The IPO market has been largely dormant across the tech sector for the past three years, and within digital health, it’s been almost completely dead. After President Donald Trump announced a sweeping tariff policy that plunged U.S. markets into turmoil last month, taking a company public is an even riskier endeavor. Online lender Klarna delayed its long-anticipated IPO, as did ticket marketplace StubHub.
President Donald Trump's push to cut billions of dollars in government contracts is rattling the niche community of scientists who collect, study and share human brains. Two of the country's brain banks, which have worked with the government to store and distribute specimens to researchers studying diseases like Parkinson's and ALS for more than a decade, told POLITICO they had temporarily stopped taking new donations for fear the administration would not renew their contracts.
The partner of Theranos founder Elizabeth Holmes has raised millions of dollars for an artificial intelligence startup hoping to introduce a product that can be used in medical testing and other settings, according to two sources with direct knowledge of the endeavor who could not speak publicly because the company has not yet officially launched. The company is called Haemanthus, which is Greek for 'blood flower.'
Researchers at the University of California, San Diego School of Medicine have identified a potential new treatment for individuals with uncontrolled or treatment-resistant hypertension, a condition commonly referred to as high blood pressure. The investigational drug, lorundrostat, showed encouraging results in a recent clinical trial.